clinical trial · NCT04583618
Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.
Pneumococcal ImmunizationPneumococcal Conjugate Vaccine - formulation 1-SP0202-IIbPneumococcal Conjugate Vaccine - formulation 2-SP0202-VIPneumococcal Conjugate Vaccine - formulation 3-SP0202-VIIPneumococcal 13 - valent conjugate vaccine-Prevnar 13Pneumococcal Vaccine Polyvalent-Pneumovax 23
brief summary
Primary Objectives: * Assessed the immune response of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23 30 days after the administration of the single dose vaccination * Assessed the safety profile of the 3 SP0202 formulations, Prevnar 13 and Pneumovax 23
started
Oct 8, 2020
primary completion
Aug 9, 2021
completion
Jan 20, 2022
last updated
Sep 8, 2025
detailed description
The duration of each participant's participation was approximately 6 months.
official title
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine in Healthy Adults Aged 50 to 84 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol